Zalicus Inc (ZLCS)

[surf1944]

8:30AM Zalicus reports Z160 did not meet the primary endpoint in either of the Phase 2 clinical studies; company to discontinue Z160 clinical development (ZLCS) 4.69 : Co announced top-line results from two Phase 2 clinical studies of Z160 in chronic pain indications.

Z160 did not meet the primary endpoint in either of the Phase 2 clinical studies in patients with lumbosacral radiculopathy (LSR) and post-herpetic neuralgia (PHN). Z160 was shown to be generally safe and well-tolerated with no drug-related serious adverse events.
Based on these results, Zalicus is discontinuing the Z160 program and plans to focus efforts on Z944, its novel oral T-type calcium channel modulator in development for the treatment of pain.